ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

A Practical Approach to Using SGLT2 Inhibitors for Cardiorenal Protection

October 24, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Sodium glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the proximal tubule. SGLT2 inhibitors increase urinary glucose excretion and lower blood glucose. SGLT2 inhibitors also have non-glycemic effects on improvements in blood pressure, lipids, and uric acid levels.

Recent studies of SGLT2 inhibitors among patients with diabetes or heart failure have found a decreased risk of heart failure, cardiovascular mortality, and kidney disease progression. Because the trial medications were given in addition to standard-of-care treatments for diabetic kidney disease and heart failure, use of SGLT2 inhibitors will need to be integrated with these other treatments. Such integration may involve adjustment of diuretics, antihypertensives, and glucose-lowering medications.

This symposium reviews recently published outcome studies and offers plan for using these medications in clinical practice.

Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

Learning Objective(s)

  • Discuss the evidence from clinical trials of the cardiorenal benefits of SGLT2 inhibitors
  • Describe a treatment plan for integrating SGLT2 inhibitors into the care of patients with diabetic kidney disease or heart failure

Learning Pathway(s)

  • Hypertension and CVD
  • Diabetes and Metabolism

Moderator

  • Giuseppe Remuzzi, MD

Presentations

  • Introduction
    01:00 PM - 01:10 PM
    Giuseppe Remuzzi, MD 
  • Cardiorenal Outcomes with SGLT2 Inhibitors
    01:10 PM - 01:35 PM
    Ian H. de Boer, MD, MS
  • Integrating SGLT2 Inhibitors into the Management of Diabetes and Heart Failure
    01:35 PM - 02:00 PM
    Amy K. Mottl, MD, FASN, MPH